Paid To Wait? Eli Lilly Crashes To 2 Year Lows, Erases 6 Years Of Dividends After Failed Drug Test
Following news that its Alzheimer's drug has failed final stage trials, Eli Lilly stock is crashing this morning to 2 year lows. The 'safe haven', 'paid-to-wait' stock has tumbled almost 15% - erasing over 6 years of dividends, and sparking contagious selling across Biotech stocks.